Clinical Trial Update: A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and preliminary efficacy of LiRIS 400 mg in women with chronic interstitial cystitis with Hunner's lesions. The t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Cystitis

Drugs mentioned

• LiRIS 400 mg

Snippet

Sponsor: Allergan | Conditions: Chronic Interstitial Cystitis | Phase 1 | Status: COMPLETED | Results posted: 2015-12-18